Investigational Antiplatelet Drugs for the Treatment and Prevention of Coronary Artery Disease

Cardiology in Review

Volumn 16, Issue 5, 2008, Pages 250-259

  Zeidner, Joshua F ^a   Frishman, William H ^a,b,c   Lerner, Robert G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Adenosine diphosphatase receptor antagonists; Anti von Willebrand agents; Antiplatelet drugs; Protease activated receptor antagonists; Thrombin inhibitors; Thromboxane inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ARC 1779; BLOOD CLOTTING INHIBITOR; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; E 555; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; NITRIC ACID DERIVATIVE; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; PROTEINASE INHIBITOR; SCH 530348; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; ANTITHROMBOCYTIC AGENT; THROMBIN;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY RISK; DIABETES MELLITUS; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSPNEA; GASTROINTESTINAL TOXICITY; HEART DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LOADING DRUG DOSE; LOW DRUG DOSE; NEUTROPENIA; NONHUMAN; PATHOGENESIS; RESTENOSIS; REVIEW; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; DRUG ANTAGONISM;

CORONARY ARTERY DISEASE; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PROTEINASE-ACTIVATED; THROMBIN; VON WILLEBRAND FACTOR;

EID: 56149097961     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181804336     Document Type: Review

References (61)

1. Frishman WH, Lerner RG, Klein MD, et al. Antiplatelet and antithrom-botic drugs. In: Frishman WH, Sonenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw-Hill; 2003;259-299.
2. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482-2494.
3. Clemetson KJ. A short history of platelet glycoprotein Ib complex. Thromb Haemost. 2007;98:63-68.
4. Detwiler TC, Charo IP, Feinman RD. Evidence that calcium regulates platelet function. Thromb Haemost. 1978;40:207-211.
5. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res. 2007;100:1261-1275.
6. Ruggeri ZM. Platelets in atherothrombosis. Nature Med. 2002;8:1227-1234.
7. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled, multi-center clinical trial. Circulation. 1990;82:17-26.
8. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
9. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
10. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607-1621.
11. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.
12. Cooke GE, Goldschmidt-Clermont PJ. The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. Expert Opin Drug Saf. 2006;5:815-826.
13. Hanjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications. Cardiol Rev. 2006;14:18-25.
14. Wiviott SD. Clopidogrel response variability, resistance or both? Am J Cardiol. 2006;98:S18-S24.
15. Nguyen T, Frishman WH, Nawarskas J, et al. Variability of response to clopidogrel: possible mechanisms and clinical applications. Cardiol Rev. 2006;14:136-142.
16. Angiolillo DJ. ADP receptor antagonism. What's in the pipeline? Am J Cardiovasc Drugs. 2007;7:423-432. L'Allier PL, Ducrocq G, Pranno N, et al; for the PREPAIR Study Investigators. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens. Results from the PREPAIR randomized study. J Am Coll Cardiol. 2008;51:1066-1072. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. A multicenter randomized prospective study. J Am Coll Cardiol. 2008;51:1404-1411.
17. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION trial. J Am Coll Cardiol. 2006;48:931-938.
18. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol. 2002;40:231-237.
19. Cattaneo M. Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert Rev Cardiovasc Ther. 2007;5:45-55.
20. Hasegawa M, Sugidachi A, Ogawa T, et al. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of prasugrel, a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005;94: 593-598.
21. Jakubowski J, Payne C, Brandt J, et al. The platelet inhibitory effects and pharmokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects. J Cardiovasc Pharmacol. 2006;47:377-384.
22. Farid NA, Payne CD, Ernest CS II, et al. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol. 2008;48:53-59.
23. Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol. 2007;100:331-336.
24. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166-1173.
25. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153:66-e9-66-e16.
26. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol. 2007;50:555-562.
27. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel, a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO) TIMI-26 trial. Circulation. 2005;111:3366-3373.
28. Wiviott SD, Antman EM, Gibson M, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel - Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627-635.
29. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
30. Wiviott SD, Trenk D, Frelinger AL, et al., for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenancedose clopidogrel in patients with planned percutaneous coronary intervention. The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation. 2007;116:2923-2932.
31. Bhatt DL. Intensifying platelet inhibition - navigating between Scylla and Charybdis [editorial]. N Engl J Med. 2007;357:2078-2081.
32. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822-1834.
33. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038-1047.
34. Cannon CP, Husted S, Harrington RA, et al., for the DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST segment elevation acute coronary syndromes. Primary results of the DISPERSE-2 Trial. J Am Coll Cardiol. 2007;50:1844-1851.
35. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2N12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852-1856.
36. Tantry US, Bliden KP, Gurbel PA. AZD6140. Expert Opin Investig Drugs. 2007;16:225-229.
37. Fugate SE, Cudd LA. Cangrelor for treatment of coronary thrombosis. Ann Pharmacol. 2006;40:926-930.
38. Wang K, Zhou X, Zhou Z, et al. Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol. 2003;23:357-362.
39. Storey RF, Oldroyd KG, Wilcox KG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability, and activity in patients with acute coronary syndrome. Thromb Haemost. 2001;85:401-407.
40. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets. 2002;13:407-413.
41. Greenbaum AB, Grines CL, Bittl JA. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multi-center, randomized, placebo-and active-controlled trial. Am Heart J. 2006;151:689.e1-689.e10.
42. Antoniades C, Tousoulis D, Stefanadis C. Nitric oxide-releasing aspirin: will it say NO to atherothrombosis? Intl J Cardiol. 2007;118:170-172.
43. Fiorucci S, Mencarelli A, Mannucci R, et al. NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. FASEB J. 2002;16:1645-1647.
44. Gresele P, Momi S. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev. 2006;24:148-168.
45. Fu Y, Wang Z, Chen W, et al. Cardioprotective effects of nitric oxide-aspirin in myocardial ischemia-reperfused rats. Am J Physiol Heart Circ Physiol. 2007;293:H1545-H1552.
46. Napoli C, Aldini G, Wallace JL, et al. Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc Natl Acad Sci USA. 2002;99:1689-1694.
47. Muscara MN, Lovren F, McKnight W, et al. Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br J Pharmacol. 2001;133:1314-1322.
48. Lorusso R, De Cicco G, Beghi C, et al. Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG. Intl J Cardiol. 2007;118:164-169.
49. Jayet PY, Thalmann S, Sartori C, et al. Nitro-aspirin improves insulin sensitivity in obese subjects [abstract]. Circulation. 2004;110(Suppl III):3789.
50. Gresele P, Migliacci R, Bonizzoni E, et al. Nitroaspirin prevents effortinduced endothelial dysfunction in intermittent claudication [abstract]. Circulation. 2004;110 (Suppl III):III-520.
51. Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations of thrombin-induced human platelet activation. Eur J Pharmacol. 2006;546:142-147.
52. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879-887.
53. Xu Y, Huo Y, Toufektsian MC, et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;290:H692-H699.
54. Ray KK, Morrow DA, Gibson CM, et al. Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: an ENTIRE-TIMI 23 substudy. Eur Heart J. 2005;26:440-446.
55. Montalescot G, Philippe F, Ankri A, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE trial. Circulation. 1998;98:294-299.
56. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease. Focus on acute coronary syndromes. Circulation. 2008;117: 1449-1459.
57. Becker RC. The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort. Eur Heart J. 2005;26:421-422.
58. Lee JF, Stovall GM, Ellington AD. Aptamer therapeutics advance. Curr Opin Chem Biol. 2006;10:282-289.
59. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti-von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation. 2007;116:2678-2686.
60. Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: the first 30 years. Thromb Haemost. 2006;95:49-55.
61. Reininger AJ, Heijnen HF, Schumann H, et al. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood. 2006;107:3537-3545.